Literature DB >> 17116461

Management of sepsis.

Gina Howell1, Samuel A Tisherman.   

Abstract

Severe sepsis remains a common cause of death in surgical patients. Eradication of the septic source and supportive care has long been the mainstay of treatment. In recent years, however, early goal-directed therapy, tighter glucose control, administration of drotrecogin alfa (activated), and steroid replacement have produced improved morbidity and mortality. In the future, a better understanding of the pathophysiology of sepsis and clinical studies may further improve outcomes from severe sepsis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116461     DOI: 10.1016/j.suc.2006.08.001

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  4 in total

1.  Exogenous carbon monoxide suppresses Escherichia coli vitality and improves survival in an Escherichia coli-induced murine sepsis model.

Authors:  Wei-chang Shen; Xu Wang; Wei-ting Qin; Xue-feng Qiu; Bing-wei Sun
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

2.  Milk fat globule EGF factor 8 attenuates sepsis-induced apoptosis and organ injury in alcohol-intoxicated rats.

Authors:  Rongqian Wu; Wayne W Chaung; Mian Zhou; Youxin Ji; Weifeng Dong; Zhimin Wang; Xiaoling Qiang; Ping Wang
Journal:  Alcohol Clin Exp Res       Date:  2010-06-25       Impact factor: 3.455

3.  Human ghrelin ameliorates organ injury and improves survival after radiation injury combined with severe sepsis.

Authors:  Kavin G Shah; Rongqian Wu; Asha Jacob; Steven A Blau; Youxin Ji; Weifeng Dong; Corrado P Marini; Thanjavur S Ravikumar; Gene F Coppa; Ping Wang
Journal:  Mol Med       Date:  2009-09-18       Impact factor: 6.354

4.  Reversing established sepsis in rats with human vasoactive hormone adrenomedullin and its binding protein.

Authors:  Rongqian Wu; Shinya Higuchi; Weifeng Dong; Youxin Ji; Mian Zhou; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2008-10-10       Impact factor: 6.354

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.